Tyra Biosciences, Inc. disclosed a material event
SEC 8-KRead source ↗
Tyra Biosciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders1 buying, 3 selling1 purchase and 14 sales by directors and officers, last 12 monthsInsider trades
- Funds102 adding, 69 cuttingOf 51 active managers that changed their stake, 26 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Tyra Biosciences, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
- Volatile shares. Over the past year the shares showed annualised volatility of 67% and a beta of 0.5 against the S&P 500.
- Heavily shorted. 22.9% of the shares available to trade are sold short (10.9 days of average volume to cover).
- Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.
Latest results
- Earnings per share
- -$0.69 against an average estimate of -$0.64: missed by 7.0%
- Share reaction
- -19.8% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
- Next report
- November 4, 2026; average EPS estimate -$0.67
Price chart
- 1 day+1.2%
- 1 week+4.5%
- 1 month+4.4%
- This year-18.9%
- 1 year+34.7%
- 5 years-26.3%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 4, 2026
- Next results (est.)
- November 4, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Announcement
- Announcement
Tyra Biosciences, Inc. disclosed a material event
SEC 8-KRead source ↗ - Results
Tyra Biosciences, Inc. reported results
SEC 8-KRead source ↗
No model value for Tyra Biosciences, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Tyra Biosciences, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.23 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Tyra Biosciences, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 4, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.67 (range −$0.76 to −$0.47) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$2.64 | −31% | — | 0% |
| Next | −$2.77 | −5% | — | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +2.2% on 90 days ago. In the last 30 days, 4 analysts raised Tyra Biosciences, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$2.58 | −$2.82 |
| 60 days ago | −$2.67 | −$2.96 |
| 30 days ago | −$2.66 | −$2.87 |
| 7 days ago | −$2.64 | −$2.77 |
| Now | −$2.64 | −$2.77 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.64 | −$0.69 | −7.0% |
| Mar 2026 | −$0.59 | −$0.64 | −8.6% |
| Dec 2025 | −$0.53 | −$0.57 | −8.5% |
| Sept 2025 | −$0.51 | −$0.50 | +2.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 22.9% of tradable shares
- Days to cover
- 10.93 at average volume
- Short interest, 1 month
- −4% to October 15, 2026
- Held by institutions
- — of shares
- Held by insiders
- 2.4% of shares
- Employees
- 87 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|
| Return | |||||
| TYRA | −46% | +82% | +0% | +89% | −19% |
| Industry peers (median) | −57% | −18% | −29% | −5% | −27% |
| S&P 500 | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | |||||
| TYRA | 42% | 67% | 42% | 75% | 36% |
| S&P 500 | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | |||||
| TYRA | −63% | −37% | −51% | −58% | −53% |
| S&P 500 | −25% | −10% | −8% | −19% | −9% |
Worst fall since September 15, 2021: 83% from November 4, 2021 to June 17, 2022. Getting back needed a 496% gain, reached on January 27, 2026, 1320 days after the low.
Price behaviour
- 52-week range
- $14.28 – $39.61
- From 52-week high
- −46.1%
- vs 50-day average
- −5.5%
- vs 200-day average
- −28.5%
- Volatility (1 year)
- 67%
- Beta vs S&P 500
- 0.48
Share price after results
- Next day
- 4 up, 8 down typical move ±5.8%
- After a week
- 6 up, 6 down typical move ±7.3%
- After a month
- 8 up, 4 down typical move ±13.5%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 4, 2026 | −19.8% | +1.6% | −21.4% | −21.6% |
| May 13, 2026 | +4.7% | +1.4% | −4.2% | −22.6% |
| March 2, 2026 | −0.9% | −0.8% | +1.3% | +15.0% |
| November 5, 2025 | −4.8% | −0.7% | +3.2% | +43.3% |
| August 14, 2025 | −0.2% | −0.2% | +8.8% | +14.5% |
| May 8, 2025 | +10.5% | +0.6% | +8.0% | +12.4% |
| March 27, 2025 | −4.6% | −2.3% | −18.9% | +1.0% |
| November 7, 2024 | −5.9% | +1.2% | −4.6% | −6.5% |
| August 7, 2024 | +0.7% | +1.6% | +6.8% | +1.9% |
| May 9, 2024 | −3.8% | +0.7% | +5.9% | +10.9% |
| March 19, 2024 | +7.0% | +1.5% | −0.5% | −9.7% |
| November 7, 2023 | −6.2% | +0.4% | −3.7% | +2.5% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $2.2B
- Institutions reporting
- 169
- Shares held vs prior quarter
- ▲ 4.9%
- Positions opened / closed
- 30 / 25
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| RA Capital Management, L.P. | $390M | 12.2M | 17.6% | 0.0% |
| FMR LLC | $285M | 8.9M | 12.8% | ▲ 15.1% |
| Jupiter Topco LLC | $139M | 4.4M | 6.3% | — |
| Alta Partners Management Company, L.P. | $122M | 3.8M | 5.5% | 0.0% |
| Nextech Invest Ltd. | $114M | 3.6M | 5.1% | ▼ 12.4% |
| Tcg Crossover Management, LLC | $104M | 3.2M | 4.7% | 0.0% |
| Blackrock, Inc. | $96.8M | 3.0M | 4.4% | ▲ 36.7% |
| Price T Rowe Associates Inc | $88.9M | 2.8M | 4.0% | ▲ 182.2% |
| State Street Corp | $68.4M | 2.1M | 3.1% | ▲ 76.0% |
| Commodore Capital LP | $59.9M | 1.9M | 2.7% | ▼ 24.2% |
| Paradigm Biocapital Advisors LP | $58.4M | 1.8M | 2.6% | ▼ 11.0% |
| Vanguard Capital Management LLC | $48.2M | 1.5M | 2.2% | ▲ 34.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Tyra Biosciences, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.
Insider trading activity
Full insider history and chart Insider purchases History → $20,001 1 trade by 1 insider, last 12 months Insider sales History → $10.6M 14 trades by 3 insiders · 95% under pre-set plans
Net ▼ $10.6M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Verjee Rehan Director | September 9, 2026 | Buy | 972 | $20.58 | $20,001 |
| Kaplan Gilla Director | March 25, 2026 | Sell | 14,295 | $36.97 | $528,486 |
| Bensen Daniel Chief Discovery Officer | February 12, 2026 | Sell pre-set plan | 5,872 | $33.37 | $195,949 |
| Bensen Daniel Chief Discovery Officer | February 12, 2026 | Sell pre-set plan | 2,128 | $31.50 | $67,032 |
| Bensen Daniel Chief Discovery Officer | January 12, 2026 | Sell pre-set plan | 1,017 | $29.08 | $29,574 |
| Bensen Daniel Chief Discovery Officer | January 12, 2026 | Sell pre-set plan | 6,983 | $28.44 | $198,597 |
| More Robert J Director | December 19, 2025 | Sell pre-set plan | 10,000 | $25.00 | $250,000 |
| Bensen Daniel Chief Discovery Officer | December 12, 2025 | Sell pre-set plan | 8,000 | $22.64 | $181,120 |
| More Robert J Director | November 21, 2025 | Sell pre-set plan | 246,871 | $20.25 | $5M |
| Bensen Daniel Chief Operating Officer | November 19, 2025 | Sell pre-set plan | 49,956 | $16.32 | $815,282 |
| Bensen Daniel Chief Operating Officer | November 18, 2025 | Sell pre-set plan | 75,633 | $16.07 | $1.2M |
| Bensen Daniel Chief Operating Officer | November 17, 2025 | Sell pre-set plan | 18,572 | $16.11 | $299,195 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced
- August 4, 2026
- May 13, 2026
- March 2, 2026
- November 5, 2025
- August 14, 2025
- May 8, 2025
Recent SEC filings
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Tyra Biosciences, Inc. in brief
- What does Tyra Biosciences, Inc. do?
- Tyra Biosciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Tyra Biosciences, Inc.'s stock ticker?
- Tyra Biosciences, Inc. trades under the ticker TYRA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Tyra Biosciences, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are RA Capital Management, L.P., FMR LLC and Jupiter Topco LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Tyra Biosciences, Inc. stock?
- Over the last 12 months, Tyra Biosciences, Inc.'s directors and officers reported 1 open-market purchases and 14 sales on Form 4. The insider trading page charts every trade.
- When is Tyra Biosciences, Inc.'s next earnings date?
- Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Tyra Biosciences, Inc. announces its own schedule.
Follow research on Tyra Biosciences, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.